MONTREAL, June 25 /PRNewswire-FirstCall/ - ProMetic Life Sciences Inc. (TSX:PLI) ("ProMetic") announced today that it has further confirmed the efficacy of the prion capture resins developed by Pathogen Removal and Diagnostic Technologies Inc. ("PRDT")' in the removal of prions from different solutions, including mixtures of proteins containing high concentrations of specific proteins such as 25% albumin and 3% immunoglobulin solutions without affecting the concentration of the proteins. Plasma-derived albumin and immunoglobulin proteins are commonly used as therapeutics. Furthermore, proteins such as albumin are also regularly used as non-active stabilizing ingredients in the formulation of biopharmaceutical products.
"This has far reaching implications for the biopharmaceutical industry. It offers the opportunity to provide an additional safety element by including prion-depleted human blood-derived or animal-derived products in the formulation and manufacture of some of these high-value therapeutics," stated Mr. Pierre Laurin, ProMetic's President and Chief Executive Officer.
In addition, the evaluation of PRDT resins established their ability to efficiently remove infectious prion protein from whole human plasma, a complex mixture of hundreds of different proteins, and demonstrated that the ligands developed by PRDT targets the prion protein, and can bind that compound even under the competition of several proteins, without significantly binding any of the proteins vital for plasma.
This corroboration of the PRDT resins' performance follows on the June 10th announcement of Octopharma AG's recent implementation of PRDT's prion removal resin into their manufacturing process of Octaplas(R). For additional information on this announcement, please visit ProMetic's Newsroom at http://www.prometic.com/en/news.htm.
Dr. Patrick Gurgel, ProMetic's Senior Research Scientist a
|SOURCE PROMETIC LIFE SCIENCES INC.|
Copyright©2008 PR Newswire.
All rights reserved